Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 9Prostatic Neoplasms, Castration-Resistant 1Nonseminomatous germ cell tumor 1Neoplasms 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1

Interventions

olaparib 3enzalutamide 2darolutamide 2Prednisone 2Prednisolone 2Pluvicto 2Docetaxel 2Androgen Antagonists 2Abiraterone Acetate 2testosterone 17 beta-cypionate 1radium Ra 223 dichloride 1fludarabine phosphate 1fludarabine 1cabazitaxel 1alovudine 1abiraterone 1Standard of Care 1Radium-223 1PSMA-617 1Nivolumab 1Gonadotropin-Releasing Hormone 1Cyclophosphamide 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × cabazitaxel × 90 days × Clear all
NCT02044354 2026-04-01

CABA-DOC

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Completed
195 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡